LUX Lung 2 clinical cancer trial

Boehringer Ingelheim

LUX-Lung 2 is a multicentre Phase II, randomised, open-label, single arm trial of afatinib* in patients with advanced lung cancer that were untreated or progressed after one course of chemotherapy. Patients were tested for activating EGFR mutations prior to their inclusion in the trial.

Personalising cancer care and the future of cancer treatments

Mode of action afatinib* slide kit

LUX-Lung 3 Clinical Trial Infographic

LUX Lung 1 clinical trial fact sheet

Boehringer Ingelheim to commence Lux Lung 3 study investigating the role of BIBW 2992* as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations

BIBF 1120 in ovarian cancer

Lux lung 6 cancer clinical trial

Breast Cancer Backgrounder

Webcast South Korea, the evolution of lung cancer care

Press Release: LUX-Head & Neck 1 & 2 Trial Initiation

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on